Day three of the biotech dog and pony show saw one pharma company that unequivocally wants and needs to buy.
After Monday’s celebrations the sector gets down to discussing the difficult business of actually selling and making money from drugs.
The takeovers of Loxo and Celgene put M&A back on the agenda, and positive clinical readouts from Sage and Axsome add to the celebratory mood.
Alnylam appears to have turned its Onpattro launch around, but is adamant that investors should have been more patient all along.
Despite several changes of direction SAGE-217 comes out positive in postpartum depression, setting Sage Therapeutics up as a takeover target.
Novavax awaits phase III data with its respiratory syncytial virus vaccine ResVax, while Mallinckrodt hopes to bounce back with its next big pipeline hope, CPP-1X plus…
Shutdown or no, drug reviews are still under way, giving the sector something to look forward to as 2019 kicks off.
Allergan, Biogen, Bristol-Myers Squibb and Lilly follow Pfizer and Merck & Co on price increases, and there could be more to come at JP Morgan.
Urogen is gearing up to release the results of a pivotal trial of its lead asset – and so is Mediwound.